All In Biotech

Drug Trial Radar · NCT04746911

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

An Open Label, 4-Week, Phase 2, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Pediatric Subjects (Ages 2 to 5 Years Old) With Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Mar 1, 2021

Primary completion

May 11, 2022

Study completion May 11, 2022

Sponsor

Lead sponsor
Arcutis Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:

Conditions

  • Psoriasis
  • Plaque Psoriasis

Interventions

  • ARQ-151 cream 0.3%Drug

    ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3%Time frame: Weeks 2 and 4: 1 hour predose
  2. Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3%Time frame: Weeks 2 and 4: 1 hour predose
  3. Number of Participants With an Adverse Event (AE)Time frame: Up to 4 weeks
  4. Number of Participants With Application Site ReactionsTime frame: Up to 4 weeks

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Arcutis Clinical Site 603

    Mountain Brook, Alabama

  • Arcutis Clinical Site 604

    Scottsdale, Arizona

  • Arcutis Clinical Site 609

    Fountain Valley, California

  • Arcutis Clinical Site 618

    Los Angeles, California

  • Arcutis Clinical Site 608

    Los Angeles, California

  • Arcutis Clinical Site 611

    Rancho Santa Margarita, California

  • Arcutis Clinical Site 610

    Boca Raton, Florida

  • Arcutis Clinical Site 602

    Coral Gables, Florida

  • Arcutis Clinical Site 613

    Delray Beach, Florida

  • Arcutis Clinical Study Site 628

    Miami, Florida

  • Arcutis Clinical Site 607

    Miami, Florida

  • Arcutis Clinical Site 627

    West Lafayette, Indiana

  • Arcutis Clinical Site 606

    Arlington, Texas

  • Arcutis Clinical Site 619

    Frisco, Texas

  • Arcutis Clinical Study Site 619

    Frisco, Texas

  • Arcutis Clinical Site 605

    Houston, Texas

  • Arcutis Clinical Site 621

    Toronto, Ontario, Canada

  • Arcutis Clinical Site 630

    Santo Domingo, Dominican Republic

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.